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Abstract
Background: Isolation of human antibodies using current display technologies can be limited by constraints on protein
expression, folding and post-translational modifications. Here we describe a discovery platform that utilizes self-inactivating
(SIN) lentiviral vectors for the surface display of high-affinity single-chain variable region (scFv) antibody fragments on
human cells and lentivirus particles.
Methodology/Principal Findings: Bivalent scFvFc human antibodies were fused in frame with different transmembrane
(TM) anchoring moieties to allow efficient high-level expression on human cells and the optimal TM was identified. The
addition of an eight amino acid HIV-1 gp41 envelope incorporation motif further increased scFvFc expression on human
cells and incorporation into lentiviral particles. Both antibody-displaying human cells and virus particles bound antigen
specifically. Sulfation of CDR tyrosine residues, a property recently shown to broaden antibody binding affinity and antigen
recognition was also demonstrated. High level scFvFc expression and stable integration was achieved in human cells
following transduction with IRES containing bicistronic SIN lentivectors encoding ZsGreen when scFvFc fusion proteins were
expressed from the first cassette. Up to 10
6-fold enrichment of antibody expressing cells was achieved with one round of
antigen coupled magnetic bead pre-selection followed by FACS sorting. Finally, the scFvFc displaying human cells could be
used directly in functional biological screens with remarkable sensitivity.
Conclusions/Significance: This antibody display platform will complement existing technologies by virtue of providing
properties unique to lentiviruses and antibody expression in human cells, which, in turn, may aid the discovery of novel
therapeutic human mAbs.
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Introduction
Monoclonal antibodies (mAbs) have been used with increasing
frequency to treat a wide spectrum of human diseases, including
heart disease, infections and immune disorders [1–5]. The mAb
based immunotherapies are now standard of care in an increasing
number of human cancers including Erb2+ breast cancer, Non-
Hodgkin’s Lymphoma, colon cancer and others [1,6,7].
Since 2001, human mAbs developed through recombinant
DNA techniques have constituted the largest number entering
clinical study [1]. This shift, toward de novo human mAb isolation
and their clinical use, is in part due to new antibody display and
other library screening techniques, which are now being exploited
to isolate human antibodies with high affinity and specificity. The
microbial surface display technologies for screening antibody
libraries include phage, yeast and bacteria. Phage-display is widely
used due to its simplicity, versatility and ability to be adapted to
many specific conditions, including selection on whole cells and
tissues [8]. Yeast and bacteria display platforms have several
advantages over the phage system including use of flow-cytometry
and sorting techniques to enable finer affinity discrimination of
selected antibodies [9,10]. Among the non-microbial systems is
ribosomal display that has the capacity to screen libraries of
greater size as well as facilitating diversity and efficient antibody
maturation in vitro.
Although isolation of human antibodies from the above
mentioned systems has been successful, there can be unexpected
problems with subsequent therapeutic mAb development due to
constraints of protein expression, correct folding and post-
translational modifications. This has been particularly true for
antibodies isolated by phage-display technology. There has been
great interest in screening antibodies directly from mammalian
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3181cells due to their ability to provide proper posttranslational
modification, as well as the existence of the natural chaperones
that assist in antibody folding. Animal cells have been used for the
direct screening of hypermutating antibodies [11,12] and during
antibody selection from a retroviral-antibody display library [13].
Transient antibody expression on the surface of human 293T has
also been recently reported as a system to perform in vitro affinity
maturation of human antibodies [14]. Furthermore, sulfation of
tyrosine residues in the CDR residues of human antibodies can
markedly affect antigen recognition [15,16] and contribute
bidirectionally to the binding activity of antibodies [17]. These
latter findings suggest that antibody selection and expression on
the surface of human cells may not only identify a population of
antibodies that would be difficult or even impossible to detect in
other microbial or cell-free display systems, which lack the ability
to sulfonate CDR tyrosines, but may also be able to select against
antibodies that may otherwise loose activity upon transferring to
mammalian expression systems.
In this report, we show that bivalent functional human scFvFc
fusion proteins can be efficiently expressed on surface of lentiviral
transduced human cells, as well as incorporated onto the surface of
lentiviral particles. The displayed scFvFc antibodies can undergo
post-translational CDR tyrosine sulfation. Combined magnetic
bead and FACS selections on transduced human cells have
provided, proof-in-principle, that 10
6-fold enrichments of specific
antibodies can be achieved in a single, rapid selection step. In
addition, scFvFc displaying human cells could be used directly in
functional biological screens with remarkable sensitivity.
Results
Optimization of scFv surface expression in mammalian
cells
PS11 scFv, an antibody targeting the Tat-recognition motif
(TRM) of cyclin T1 [18], was chosen as a model for optimizing
functional expression of scFv on the surface of mammalian cells.
To gain bivalency and increase the sensitivity of detecting antigens
bound to surface antibody, the PS11 scFv was expressed as an
scFvFc fusion protein [18–20]. For anchoring to the cell
membrane, PS11 scFvFc protein was fused, in frame, to a
transmembrane (TM) moiety. TM domains of HIV-1 gp41, CD8
and CD28 were tested for maximal surface expression of the
scFvFc. As shown in Figure 1, all anchoring moieties consist of a
short extracellular region, an entire TM domain and a cytoplasmic
tail. Eight residues of the most membrane-proximal HIV-1 gp41
cytoplasmic tail, previously shown to provide a putative ‘‘envelope
(env) incorporation motif’’ [21], were also tested for their ability to
promote efficient pseudotyping of the scFvFc fusion proteins onto
HIV virions or subsequently the cell surface, as a direct fusion to
the gp41 TM or attached to the carboxy terminus of the CD8 or
CD28 cytoplasmic tails.
Surface expression of the PS11-scFvFc-TM proteins was initially
analyzed by FACS analysis of transiently transfected 293T cells,
stained with APC-conjugated anti-human-Fc antibody (Figure 2).
While transfection efficiency with each of the constructs was
relatively equal, as monitored through the expression level of a co-
transfected GFP plasmid (data not shown), depending on the
Figure 1. Diagram of constructs used in the study. ScFv antibodies were inserted between the leader peptide (LP) and the Fc region of a
human IgG1 molecule. The Fc domain was linked in-frame to a short segment of extracellular domain of HIV-1 gp41 (blue), CD8 (green) or CD28
(purple), followed by their respective transmembrane domains (TM; horizontal stripes) and cytoplasmic domains (vertical stripes). In the case of HIV-
gp41, the last 19 residues of the extracellular region (solid blue) are followed by a TM spanner (22 residues; blue horizontal stripes) and a cytoplasmic
tail (blue vertical stripes). Either the full length 151 residues of the cytoplasmic domain or a truncated region that includes only the first eight residues
of the cytoplasmic tail were used. Numbering is according to p160 of HIV-1 HXB2. For CD8, the most membrane-proximal 12 residues of the
extracellular domain (solid green) and 11 residues of the cytoplasmic domain (green vertical stripes) flank 21 residues of the TM region (horizontal
green stripes). For CD28, an extracellular region consisting of 40 residues (solid purple) and a cytoplasmic region of 13 residues (purple vertical
stripes) flank the 27-residue TM domain (horizontal purple stripes). To facilitate scFvFc-TM incorporation into virions, an eight-residue ‘‘env
incorporation motif’’, which encodes the membrane proximal part of the gp41 cytoplasmic tail (NRVRQGYS; single blue line-amino acids 706–713),
was attached to the carboxy-terminal ends of the cytoplasmic domains of CD8 and CD28. A nine amino acid C9 tag (red box) is positioned at C-
terminus of all Fc domains to facilitate detection/quantitation of scFvFc expression on the cell surface. The gene cassette was cloned into pCDNA3.1
or the modified pHAGE lentiviral vector between Sfi-I and Pac-I sites. A CMV promoter controls expression of the scFvFc-TM transgenes.
doi:10.1371/journal.pone.0003181.g001
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PLoS ONE | www.plosone.org 2 September 2008 | Volume 3 | Issue 9 | e3181Figure 2. Optimization of scFvFc cell-surface expression using different transmembrane domains. 293T cells were transfected with the
pcDNA 3.1 based constructs encoding PS11-scFvFc antibodies of different configurations as described in Figure 1 and labeled under each lane in
Panels a and b. pcDNA3.1-CMV-GFP was co-transfected as an internal control for transfection efficiency. At 48 hours post transfection, cells were
harvested and analyzed for GFP and scFv-Fc expression by FACS analysis. Panels a and b, represent results from FACS analysis of the percentage of
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PS11-scFvFcwereobserved inboth the percentage ofcellsthat were
positive for scFvFc expression (Panel a), and more pronounced by
their respective MFI values (Panel b). The data indicate that PS11-
scFvFc antibodies anchored by the TM of CD8 (lanes 6 and 7) or
CD28 (lanes 8 and 9) were highly expressed on the surface of
mammalian cells, compared to PS11-scFvFc fused to HIV-gp41
TM (either a long or short cytoplasmic tails; lanes 4 and 5) that were
poorly surface expressed, and their MFI values were low.
To directly visualize the distribution and localization of scFvFc-
TM expression, cells transfected with a bicistronic IRES-ZsGreen
expression vector encoding PS11-scFvFc-gp41 (665–856), or
PS11-scFvFc-CD28-gp41 (706–713) were labeled with a rhoda-
mine conjugated anti-human Fc antibody for immunofluorescence
analysis. As shown in Figure 2c, cells expressing PS11-scFvFc-gp41
(665–856) demonstrated punctate staining with large aggregates
and exhibited an overall low level of cell-surface expression (image
b). In contrast, PS11-scFvFc-CD28-gp41 (706–713) proteins were
evenly distributed on the cell surface and also had a reticular
staining pattern, consistent with efficient ER folding and
expression (image c). As a control, rhodamine conjugated anti-
human Fc staining was not detected on cells transfected with
ZsGreen encoding vector alone (image a). These results are
consistent with the FACS data shown in Figure 2a and 2b. Low
expression and possible aggregation of PS11-scFvFc-gp41 (665–
856) may be a result of poor folding, as the natural Fc moiety
forms dimers, while gp41 forms trimers through its TM. Finally,
radio-immunoprecipitation and SDS-PAGE analysis confirmed
that the membrane bound PS11-scFv-CD28-gp41 (706–713)
protein was dimeric (Figure 2d).
Specific antigen binding by mammalian cell-surface
expressed scFvFc-TM antibodies
To confirm that the cell surface-anchored PS11-scFvFc remains
functional for binding to its antigen, 293T cells transfected with
different PS11-scFvFc-TM fusion proteins were stained with a
biotinylated-TRM peptide and analyzed by FACS, using APC-
conjugated streptavidin. As seen in Figure 3, all PS11-scFvFc-TM
proteins were functional for binding the biotinylated TRM
peptide. The binding was specific, since an irrelevant X48-scFvFc,
recognizing a biotinylated CXCR4 peptide [17], showed only a
relatively low level of APC-streptavidin staining (lane 4). Overall,
the PS11-scFvFc-CD8-gp41 and PS11-scFvFc-CD28-gp41 pro-
teins were the most competent in binding the peptide and
exhibited higher levels of peptide binding compared to the
corresponding constructs without the envelope incorporation
motifs (Figure 3b, compare lanes 8 and 10 to lanes 7 and 9,
respectively). This result suggests that this motif may stabilize
surface antibody expression, by promoting its proper folding and
membrane association. The lower surface expression of PS11-
scFvFc linked to the gp41 TM region (Figure 2a and b) lead to a
dramatically lower binding capacity to the biotinylated TRM
peptide, as compared with the PS11-scFvFc fused to the CD8 or
CD28 TM regions, evidenced by both a lower percentage of
antigen binding cells and MFI values (Figure 3a and b; compare
lanes 5 and 6 with lanes 7 and 9).
Tyrosine sulfation of the mammalian cell-surface
expressed scFvFc-CD28-gp41 antibodies
We have demonstrated that in self-reactive human anti-CXCR4
antibodies, tyrosine sulfation occurs in novel areas of the V-region
genes and contributes bidirectionally to antibody binding activity
[17]. To determine if tyrosine sulfation could also occur on surface
displayed scFvFc, the self-reactive human anti-CXCR4 antibodies
X20- and X48-scFv were analyzed as scFvFc-CD28-gp41 (706–
713) fusion proteins. Radioimmunoprecipitation studies confirmed
that sulfation indeed occurred in the surface displayed X20-
scFvFc-CD28-gp41 but not with X48-scFvFc-CD28-gp41
(Figure 3c, compare lower lanes 3 and 2, respectively). Treatment
of transfected cells with sodium-chlorate, a sulfation inhibitor
[15,22], decreased expression but more significantly abolished
sulfation of scFvFc proteins (Figure 3c lower and upper panels,
respectively). This is consistent with the results for each
corresponding soluble scFv, where sulfation was mapped to
tyrosine in VH CDR2 and VL FW3 regions of X20 and required
for maximal binding and antigen recognition activity [17].
Incorporation of functional scFvFc-TM proteins into
lentivirus particles
The IgG leader-scFvFc-CD28/CD28-gp41 (706–713) coding
sequences were next cloned into the first cassette of a bicistronic
self-inactivating (SIN) lentivector containing an IRES-ZsGreen
reporter gene. Viruses encoding PS11-scFvFc, X48-scFvFc, as well
as two SARS-CoV specific antibodies 80R-scFvFc (19, 23) and
11A-scFvFc (Sui et al, submitted) that recognize Tor2 or GD03
Spike protein, respectively, were produced through co-transfecting
cells with HIV packaging plasmid and a VSV-G envelope DNA
plasmid providing surface binding and fusogenic activity for viral
entry. These viruses were analyzed for incorporation of scFvFc
into the viral envelope and their capacity to bind specific antigens;
and were further used to establish a mammalian cell display of
surface-bound antibodies through transduction.
Incorporation of scFvFc-TM was first examined by western blot
analysis of equal amounts of viral particles, as determined by p24
levels (Figure 4a, lower panel). Using an anti-human Fc antibody,
both PS11-scFvFc-CD28-gp41 (706–713) and PS11-scFvFc-CD28
were detected in the purified viral particles (Figure 4a, upper
panel, lanes 2 and 3, respectively), while a control CMV-GFP
lentivirus showed no reactivity (upper lane 1). Most importantly,
the gp41 (706–713) env incorporation motif-encoding viruses
exhibited higher Fc expression (compare upper lanes 2 and 3),
confirming a more efficient incorporation of the PS11-scFvFc-
CD28-gp41 into lentiviral particles, which is in agreement with the
results obtained in Figure 3b.
cells that are positive for APC-anti-human Fc staining (a) and their respective MFI values (b). Error bars represent the standard deviation of the
average of three experiments. Panel c. Cellular localization of the PS11-scFvFc-TM analyzed by confocal immunomicroscopy. 293T cells were
transfected with either ZsGreen expression vector alone, or with a bicistronic vector expressing both the PS11 scFvFc-TM fusion proteins and
ZsGreen. At 48 hours post transfection, cells were stained with a rhodamine-conjugated anti-human Fc for the detection of scFvFc expression as
visualized by a confocal microscope. Image a, cells transfected with ZsGreen only vector; Images b and c, cells transfected with vectors expressing
either PS11-scFvFc-gp41 (665–856)-IRES ZsGreen or PS11-scFvFc-CD28-gp41 (706–713)-IRES-ZsGreen, respectively. Absence of the ZsGreen
fluorescence in some of the APC+ cells is likely the result of low level expression of ZsGreen from the second cassette of the bi-cistronic message.
Panel d. PS11-scFv-CD28-gp41 is present as a dimer in transfected cells. 293T cells expressing pCDNA3.1-PS11-scFvFc-CD28-gp41 fusion protein were
metabolically labeled with [
35S]-cysteine and [
35S]-methionine mixture. Cell lysates were immunoprecipitated with protein A sepharose beads,
resuspended with 26SDS non-reducing (lane 1) or reducing buffer (lane 2), and subjected to SDS-PAGE and autoradiogram.
doi:10.1371/journal.pone.0003181.g002
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cells, an immunostaining protocol was performed to confirm that
viral particles incorporated the scFvFc fusion proteins. Confocal
microscopic images shown in Figure 4b indicated that viruses
expressing PS11-scFvFc-CD28-gp41 (706–713) on their surface
were stained with both anti-HIV-1 p24 antibody (image a) and
anti-human Fc antibody (image b). Merging of the two staining
profiles confirmed co-localization of the core with scFvFc (image
c). Control CMV-GFP viral particles, with no scFvFc molecules on
their surface, stained positively with the anti-p24 antibody only
(data not shown).
To further verify that scFvFc-CD28-gp41 (706–713) proteins
are displayed on the surface of lentivirus and remain functional, a
virion capture experiment was performed. Equal amounts of viral
particles [based on reverse transcription (RT) value], expressing on
their surface either PS11- or 11A-scFvFcs, were incubated in a 96-
well plate where wells were coated with either biotinylated TRM
peptide (PS11-scFvFc specific) or GD03-Fc protein (11A-scFvFc
specific) antigen. BSA served as a negative control. Following
binding and extensive washing, the amount of captured viral
particles in each well was determined by RT assay. As shown in
Figure 4c, each virus bound to its own target with a very high
selectivity/specificity. Hence, recombinant lentiviral particles
could be efficiently pseudotyped with functionally intact scFvFc-
CD28-gp41 fusion proteins.
Characterization of scFvsFc expressed on the surface of
lentivirus transduced cells
To establish conditions for mammalian cell display of scFvFc
antibodies, 293T cells were transduced with PS11-scFvFc-CD28-
gp41-IRES-ZsGreen encoding lentiviruses. As shown in Figure 5a,
transduced cells efficiently expressed both PS11-scFvFc, as
Figure 3. Cell surface expressed scFvFc proteins bind their cognate antigens. 293T cells were transfected with the same constructs as
described in Figure 2 and labeled under each lane in Panels a & b. Two additional constructs encoding antibodies against CXCR4, X20- and X48-
scFvFc-CD28-gp41, were also transfected. pcDNA3.1-CMV-GFP was again co-transfected as an internal control for transfection efficiency. At 48 hours
post transfection, cells were harvested and stained for biotinylated-TRM and streptavidin-APC, followed by FACS analysis. GFP expression was also
analyzed to ensure equal transfection efficiencies. Panel a and b, depict the percentage of positive cells that express a functional PS11 scFvFc as
determined by staining with streptavidin-APC (Panel a) and their respective MFI values (Panel b). Error bars represent the standard deviation of the
average of three experiments. P values,0.05 above the designated bars, represent statistically significant difference in MFI values. Panel c. Post-
translational sulfation occurs in selected surface displayed scFvFc antibodies. 293T cells expressing cell surface X48 or X20-scFcFc-CD28-gp41 fusion
proteins (lanes 2 and 3, respectively) were labeled with [
35S]-cysteine and [
35S]-methionine mixture (upper panel; Cys/Met) or with [
35S]-sulfate (lower
panel; SO4) with or without 100 mM sodium chlorate treatment. Cell lysates were immunoprecipitated with protein A sepharose beads, washed and
analyzed by SDS-PAGE and autoradiography. pcDNA3.1 backbone empty vector was also used as negative control (lane 1).
doi:10.1371/journal.pone.0003181.g003
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transgene expression could be a result of either higher sensitivity of
APC-anti-human Fc staining and/or less efficient CAP-indepen-
dent IRES driven expression of ZsGreen. Importantly, cell-surface
expression of scFvFc was detectable at very low multiplicity of
infection. Quantification analysis revealed that at MOI of 1, there
was about 5000–8000 of PS11-scFvFc-CD28-gp41 surface ex-
pressed molecules per transduced human cell (see Material and
Methods for details on quantification methods).
Antigen binding specificity of surface expressed scFvFcs were
confirmed by incubating cells transduced with CD28-gp41-IRES-
ZsGreen lentiviruses encoding either 11A-, PS11- or X48-scFvFc
with biotinylated antigens, followed by APC-streptavidin staining.
As shown in Figure 5, upon incubation with its specific biotinylated
GD03-Fc protein antigen, 11A-scFvFc expressing cells could be
easily detected (Panel c), while the control PS11-scFvFc expressing
cells exhibited only background levels of APC-streptavidin staining
(Panel b). Similarly, following incubation with a biotinylated N-
terminal CXCR4 peptide, 37% of cells transduced with the X48-
scFvFc-CD28-gp41-IRES-ZsGreen lentivirus stained positive with
streptavidin-APC (Figure 5d). In contrast, only background staining
was detected when the same transduced cells were incubated with
biotinylated GD03-Fc protein. Comparable results were seen with
PS11-scFvFc, which specifically binds TRM peptide but not an
irrelevant GD03-Fc protein.
Selection and enrichment of rare scFvFc antibodies
displayed on the surface of lentivirus transduced human
cells
To determine if transduced cells expressing scFvFc fusion
proteins on their surface could serve as a platform for isolating new
scFvs, 11A-scFvFc- scFvFc-CD28-gp41 and PS11-scFvFc-CD28-
gp41 cells were mixed at decreasing concentrations of the former
Figure 4. Functional scFvFc are incorporated into lentivirus particles. Panel a. An HIV-1 gp41 incorporation motif enhances scFvFc
incorporation into viral particles-equal loads of lentiviruses encoding ZsGreen (lane 1), PS11-scFvFc-CD28-gp41-IRES ZsGreen (lane 2) or PS11-scFvFc-
CD28-IRES ZsGreen (lane 3) were subjected to SDS-PAGE analysis, followed by western blotting using either HRP-conjugated anti-human Fc (upper
panel) or anti-HIV-1 p24 (lower panel) antibodies. Panel b. Immunostaining of viruses. Viral particles were attached to Hela cells for 2 hour at 4uC.
Cells were then fixed and stained with anti-HIV p24 antibody followed by Cy2-conjugated anti-mouse IgG or a rhodamine-conjugated anti-human Fc
for surface Fc staining. Following these procedures, cells were washed and analyzed by confocal microscope. Shown separately are viruses stained for
detection of p24 (image a) and scFvFc (image b) along with a merged image (image c). Panel c. Antigen specific capture of lentiviruses displaying
corresponding scFvFc antibodies. Equal amounts of lentivirus particles expressing on their surface either the PS11-scFvFc or the 11A-scFvFc were
loaded on a 96-well plate that was coated with the following specific antigens: TRM-peptide (PS11 specific), GD03-Fc (11A specific) or BSA. Following
incubation to allow capture of the viruses to the antigens, wells were washed extensively and viral particles were eluted and quantitated by RT assay.
Presented are normalized RT counts, where RT counts of particles bound to their antigens were divided by the RT counts of virus bound to the BSA
control. Values are the average of duplicated samples and data are representative of two separate experiments.
doi:10.1371/journal.pone.0003181.g004
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evaluated. Our initial results indicated that, at one-week post-viral
transduction, a single round of selection by direct FACS sorting of
high antigen binding/ZsGreen expressing cells, resulted in a three
log enrichment of antigen specific 11A-scFvFc surface displayed
cells, from a background cell population. However, isolation of
11A-scFvFc expressing cells could not be reliably achieved at a
mixing ratio below 1:1000 (data not shown).
Figure 5. Expression of scFvFc on the surface of lentivirus transduced cells. Panel a 293T cells were transduced with increasing dilutions
(different MOIs as indicated) of lentivirus encoding the PS11-scFvFc-CD28-gp41-IRES-ZsGreen. Transduced cells were harvested, stained for Fc-surface
expression, and analyzed by FACS. Expression of ZsGreen was measured to monitor levels of transduction. The graphs depict the percentage of
transduced cells that express ZsGreen (blue diamonds) and the percentage values of transduced cells that express PS11-scFvFc as monitored by
staining with APC-conjugated anti-human Fc IgG (pink squares). Panels b and c, cell -surface expressed scFvFc proteins are functional. 293T cells were
transduced with a lentivirus encoding PS11-scFv-Fc-CD28-gp41-IRES-ZsGreen (Panel b) or 11A-scFvFc-CD28-gp41-IRES-ZsGreen (Panel c). Cells were
incubated with biotinylated GD03-Fc, a specific antigen for 11A-scFvFc, and stained for streptavidin-APC as described in Methods, and then analyzed
by FACS. Note that two clusters of cells in Panel c represent high (R2 gated) and low (R3 gated) levels of 11A-scFvFc on their surface as measured by
APC staining. These could reflect variations in cell-surface expression levels resulting from multiple integration events of the scFvFc cassette following
transduction, or the difference in transgene integration site, i.e., its proximity to active transcriptional units. R2=1390 and R3=220 are MFI values of
11A scFvFc expressing cells, where percentage of positive cells in each gate is 31% and 49% respectively. Panel d. a summary of specific antigen
binding by the scFvFc displayed on the lentivirus transduced cells. The table shows the percentage of transduced cells expressing X48-scFvFc-CD28-
gp41 or PS11 scFvFc-CD28-gp41 that bind to their cognate or irrelevant biotinylated antigens as visualized by APC staining and their corresponding
MFI values.
doi:10.1371/journal.pone.0003181.g005
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sensitivity for specific antibody detection. Lentivirus transduced
cells were pre-sorted for ZsGreen expression soon after transduc-
tion. Upon further propagation, 11A- and PS11-scFvFc cells were
mixed at different ratios; incubated with a fixed concentration of
biotin-GD03-Fc protein and streptavidin-APC; and an enrichment
step, using MACS-anti-APC microbeads (Miltenyi), was per-
formed prior to FACS analysis and sorting of streptavidin-APC
positive cells. FACS analysis showed that the enrichment
procedure was highly efficient at cell mixing ratio of 1:10
6,
reaching at least 45-fold (compare Figure 6a R2 gates of left and
middle panels; note 0.1% cells within R2 gate are non-
distinguishable from a background value). Following magnetic
bead enrichment, high (R2 gate) and low (R3 gate) APC-stained
and ZsGreen expressing cells were again sorted and the two cell
populations (about 500–1000 cells) were propagated for one week.
A portion of cells was further propagated to reach a sufficient
number for re-staining with biotinylated GD03-Fc protein and
APC-conjugated streptavidin, while scFv genes from the remain-
ing cells were rescued by PCR amplification of genomic DNA for
rapid recloning and scFv DNA sequence analysis. As shown in
Figure 6a (right panel), upon propagation and re-staining, the
majority of originally high APC staining cells were positive for
GD03-Fc binding (81% within the R2 gate), while cells isolated
from R3-gate expressed low levels of ZsGreen and human Fc
staining, but did not bind to biotin-GDO3-Fc (data not shown).
DNA analysis confirmed that 51/56 of the clones generated from
the R2-gated cells were positive for the 11A scFvFc gene
(Figure 6b). In contrast, 40/45 clones from the R3-gated cells
encoded the PS11 scFvFc gene and only 2/45 clones expressed the
11A scFvFc. Overall, magnetic beads enrichment combined with
FACS sorting of high antigen binding/ZsGreen expressing cells
resulted in a 10
6 fold-enrichment of antigen binding cells in a
tandem two-step round of selection.
Neutralization of infection mediated by cell-surface
displayed scFvFc
It was next determined if transduced human cells expressing the
unique surface anchored scFvFc could be used directly in a
biological screen. The anti-SARS-CoV 80R antibody was chosen
as a model system for these studies [19,23]. Luciferase expressing
lentivirus pseudotyped with the cognate Tor2 Spike protein was
absorbed with increasing numbers of 80R-scFvFc or irrelevant
PS11-scFvFc expressing cells, prior to their single round infection
of permissive cells expressing the SARS-CoV receptor, ACE-2.
Non-specific virus absorption by scFvFc expressing 293T cells was
Figure 6. Selection of rare scFvFc expressing cells by a two-step magnetic bead and FACS sorting procedure. 293T cells were
transduced with either PS11-scFvFc-CD28-gp41-IRES-ZsGreen or 11A-scFvFc-CD28-gp41-IRES-ZsGreen encoding lentiviruses. These two transduced
cell populations were mixed at different 11A- to PS11-scFvFc ratios with a total cell number of ,10
9. Mixed cells were incubated with the biotinylated
GD03-Fc protein antigen and APC-streptavidin. APC-positive cells were subjected to an enrichment using anti-APC magnetic micro-beads followed by
FACS sorting. Cells from either R2 gate (high APC expressing cells) or R3 gated (low APC expressing cells) were isolated, propagated, re-stained for
biotin-GD03-Fc binding and also analyzed for their scFv gene content by PCR rescue and DNA sequencing. Panel a, the FACS dot-blot profiles of APC-
and ZsGreen positive cells within the 11A:PS11 scFvFc expressing cell population (initial mixing ratio at 1:10
6), before magnetic beads enrichment (left
panel), following magnetic bead enrichment (middle panel), and the R2 gated cells after sorting and expansion (right panel). Panel b, DNA
sequencing results of individual clones recovered from the R2 or R3 gated pools of cells sorted from different 11A:PS11 scFvFc expressing cell ratios
(1:10
3–1:10
6). Note that the irrelevant sequencing data are most likely originated from cloning background.
doi:10.1371/journal.pone.0003181.g006
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in Figure 7, close to 100% neutralization of TOR2 pseudotyped
virus infection was achieved following incubation with 80R-scFvFc
surface expressing cells as compared with 40% inhibition seen by
incubation with the PS11 scFvFc expressing cells. In contrast,
neither PS11 nor 80R scFvFcs could neutralize the infection of
permissive cells by VSV-G pseudotyped particles. Thus, very few
numbers of transduced human cells expressing a unique scFvFc
can be used directly in biological screens with exquisite sensitivity.
Discussion
This study demonstrates that human cells, the natural host of
human antibodies, can serve as a scaffold for antibody surface
expression, screening and isolation using lentivirus display. Several
thousand functional, bivalent scFvFc fusion proteins were stably
expressed on the surface of human cells. The scFvFc antibodies
when fused to the CD28/CD8 transmembrane moieties were
evenly distributed on the cell surface. A number of technical
features of this lentiviral display system were explored in this study
and deserve further comment.
First, transduction of human cells with a self-inactivating,
bicistronic lentiviral vector encoding scFvFc-CD28-gp41 and
ZsGreen proteins, combined with magnetic beads enrichment
and FACS sorting, resulted in a 10
6-fold enrichment of specific
antibody expressing cells in one single tandem, two-step
procedure, to levels comparable or superior to those achieved by
other microbial display systems [24,25]. Together with optimized
scFv PCR rescue and re-expression, this system should allow the
development of rapid, iterative antibody enrichment procedures.
Indeed, in the scFv gene PCR rescue experiment described in
Figure 6b, only one week of cell propagation was used and shorter
times are clearly possible. It should be noted that two cell
populations were commonly detected as low (R3 gate) and high
(R2 gate) ZsGreen expression and GD03-Fc antigen binding. This
occurred despite optimized amounts of biotinylated GD03-Fc
protein that were used to limit APC-streptavidin cross-reactive
staining of irrelevant PS11 scFvFc transduced cells (Figure 5b).
Sequencing analysis confirmed that the majority of the R3-gated
cells expressed the irrelevant PS11 scFvFc, while the vast majority
of the R2-gated cells encoded 11A scFvFc (Figure 6b). Thus,
careful consideration of the background threshold for each
antigen, and sorting for only high antigen binding and ZsGreen
expressing cells, are useful guidelines to maximize the recovery of
antigen binding positive cells. In addition, the positive signal to
noise MFI ratio could potentially be increased through adjusting
levels of biotin conjugation to an antigen probe or through an
extra biotin/avidin amplification step. Initial MOI for transduc-
tions should also be controlled to ensure both library diversity and
antibody expression.
Second, although not explored in detail in this study, human B-
cells are also efficiently transduced and display high levels of
scFvFc-CD28-gp41 antibody on their surface (data not shown).
The endogenous biochemical pathways that are responsible for
hypermutation of antibodies are constitutively expressed in human
B-cells [11,12] and/or can be further manipulated in an inducible
manner through retroviral gene transfer [26,27]. Thus, affinity
maturation by somatic hypermutation of displayed antibodies may
be possible and would have the advantage of occurring in stable
transduced cell lines, allowing easy subcloning and recovering of
the scFv gene.
Third, the lentiviral display system should complement existing
antibody display technologies by virtue of providing properties
unique to antibody expression in human cells. For example,
surface display of human antibodies modified by CDR tyrosine-
sulfation has not been reported for other antibody display systems.
Based on the fact that V-region tyrosine sulfation did occur on
individual surface displayed scFvs (Figure 3c), expression of scFvFc
proteins on human cells should allow isolation of antibodies
exhibiting unique properties of functional tyrosine sulfation that
could otherwise be missed through expression by ribosomal
display or other microbial display systems, where post-translational
sulfation of tyrosine residues by Golgi associated tyrosine-O-
sulfonyl transferases does not occur [28]. In addition, the
antibodies isolated via human cell screening should express
efficiently in mammalian cell systems, without the unpredictable
problems that are frequently seen in expression of antibodies
selected by phage display.
A fourth distinct advantage of this system is that the scFvFc
displaying human cells could be used in direct biological screens
with remarkable sensitivity. Studies described in Figure 7 showed
that virus neutralization activity could be detected with as few as
320 scFvFc expressing cells. Although not yet tested, it also seems
likely that transduced cells expressing bivalent surface displayed
antibodies may mediate cross-linking of antigen molecules
expressed on the surface of human target cells following co-
incubation, which could lead to positive or negative modulation of
signaling and biological responses of the target cells. This may
provide an early and direct screen to interrogate the desired
biological activity of the antibodies without the need to initiate
costly soluble antibody production and purification procedures
until the lead antibodies are identified.
Figure 7. Neutralization of SARS-CoV TOR2 spike protein
pseudotyped lentiviral infection of ACE2 expressing cells
mediated by cell-surface displayed anti-TOR2 spike 80R-
scFvFC antibodies. Single round, TOR2 spike protein pseudotyped
luciferase expressing lentiviral particles were incubated with increasing
concentrations of 293T cells expressing on their surface the 80R scFvFc
(blue diamond) or the control PS11 scFvFc (pink circle). As a control for
non-specific reporter virus absorption, a VSV-G pseudotyped luciferase
reporter lentivirus was also incubated with 80R scFvFc (red triangle) or
PS11 scFvFc expressing cells (brown square). Following incubation, the
supernatant containing remaining lentivirus was used to infect
permissive cells that express the ACE2 receptor for SARS CoV. At
48 hours post transduction, cells were harvested, luciferase activity was
measured and relative inhibition of reporter virus infection was
calculated. Asterisks in the designated points represent a statistical
analysis that was performed to verify significant differences in % of
inhibition between viral absorptions with the 80R- or PS11-scFvFc at a
specific cell number point (P,0.05).
doi:10.1371/journal.pone.0003181.g007
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scFvFc antibodies were successfully pseudotyped and expressed on
lentiviral surface (Figure 4). Thus, the scFvFc pseudotyped
lentiviral particles could also serve as a highly specific targeted
gene delivery vehicle, particularly when fusion functions are
provided in trans, as has been recently reported [29,30].
In summary, relative ease in generating high titer lentiviral
stocks [14,31–33] combined with the high permissiveness of 293T
cells to lentiviral transduction provides a platform which, we
believe, could be easily scaled up to host a large diverse human
scFvFc library. A human scFvFc-display master cell bank would
serve as a rich source for screening and isolation of high affinity
human scFv. By fully exploiting this lentivirus antibody display
system, the isolation of new human antibodies with unique
structural and biochemical properties complementing existing
display systems should be possible. Transfer of large and diverse
human scFv libraries from phage to the lentivirus mediated scFvFc
cell surface display platform and panning against common target
antigens using these alternative screening systems are ongoing.
These comparative studies, as have been similarly performed for
yeast and phage [34], will help define the value of lentivirus display
in the discovery of novel therapeutic human mAbs.
Materials and Methods
Construction of mammalian cell surface display
All scFv antibodies used in this study were originally derived
from the Mehta I/II non-immune human scFv-phage libraries
[18]. ScFv were cloned into a pcDNA 3.1-based expression vector
as an Sfi-I/Not-I 856 bp insert, and fused in frame with a human
Fc-region (hinge-CH2-CH3) that had been amplified by PCR and
cloned into pCDNA 3.1 as a Not-I/Xba-I fragment. Transmem-
brane (TM) anchoring moieties were amplified by PCR, using the
appropriate primers and templates (sequences available upon
request) and were cloned, in-frame, as Xba-I/Pac-I digested PCR
fragments, into the pCDNA 3.1-PS11-scFvFc expression vector. A
C9 sequence [34] was inserted N-terminus of all TM domains.
Plasmids DNA were sequenced and verified for cell-expression.
FACS analysis of functional expression of scFvFc on the
surface of transiently transfected cells
293T cells were seeded a day before transfection on a 6 well
plate. At the day of transfection, the 95% confluent cells were co-
transfected with 4 mg of each of the plasmids DNA (see Figure 1)
and 0.1 mg of pCDNA3.1-CMV-GFP, using lipofectamine 2000
(Invitrogen). APC-conjugated anti-human Fc antibody (Jackson
ImmunoResearch) was used to determine cell-surface expression
level of scFvFc. 5610
5 293T cells were harvested using 5 mM
EDTA at 48 hour post transfection, washed with PBS, and
incubated on ice for 1 hour with a PBS staining solution
containing 1 ml of APC-conjugated anti-human Fc antibody
(Jackson ImmunoResearch) and 2% BSA per sample. Following
incubation, cells were washed 3 times with PBS+2% BSA and
analyzed by FACS. Mock- transfected cells incubated with the
APC-conjugated anti-human Fc antibody were used as controls.
Transfection efficiency of each sample was verified through GFP
expression and analyzed concurrently by FACS.
To analyze if cell-surface expressed PS11-scFvFc proteins
remain functional for specific antigen binding and whether the
different TM domains have an effect on scFvFc function, 293T
cells were transiently transfected and harvested as described above
followed by incubation with biotinylated Tat Recognition Motif
(TRM) peptide (‘‘Macromolecular Resources’’, CO) at 10 mM
final concentration/sample on ice for 30 minutes and washed 36
with PBS+2% BSA. Cells were further incubated on ice, in the
dark, with a staining PBS solution containing 2% BSA and 1 mlo f
streptavidin-APC (Jackson ImmunoResearch). Finally, cells were
washed 3 times with PBS+2% BSA and analyzed for APC staining
by FACS. GFP expression of transfected cells was also analyzed to
standardize transfection efficiency.
Confocal microscopy analysis of scFvFc cellular
localization in transiently transfected 293T cells
293T cells were transfected with DNA encoding for a PS11-
scFvFc-CD28-gp41-IRES-ZsGreen, PS11-scFvFc-gp41-IRES-
ZsGreen or CMV-ZsGreen plasmids. The latter served as a
negative control for cells that do not express scFvFc on their
surface. At 48 hours post transfection, samples were fixed with
3.9% paraformaldehyde (SIGMA) for 30 minutes and washed
once with PBS. Subsequently, cells were incubated with PBS/
0.1 M glycine (SIGMA) for 10 minutes, followed by washing once
with PBS and permeabilization with PBS/0.05% saponin
(SIGMA) for additional 30 minutes. Upon further washing, cells
were blocked with PBS supplemented with 2% BSA and PBS/
0.05% saponin for 30 minutes and incubated in the dark with an
anti-human Fc-rhodamine antibody (Jackson ImmunoResearch)
for 1 hour. Finally, cells were washed and mounted for flurescence
microscopy by using ProLong antifade kit (Invitrogen). Images
were acquired by using BIO-Rad Radiance 2000 laser scanning
confocal microscope using a Nikon 606camera.
Metabolically radioisotope labeling and
immunoprecipitation of scFvFc-CD28-gp41 fusion
proteins
Surface displayed scFvFc post-translational sulfation analysis
was performed as described earlier [17]. Briefly, 293T cells were
transiently transfected with pCDNA3.1-scFvFc-CD28-gp41 ex-
pression plasmids using lipofectamine 2000 (Invitrogen). Eighteen
hours later, cells were washed twice with PBS. To determine
protein sulfation, one set of cells was incubated with sulfate-free
media (Sigma), supplemented with 500 mCi of [
35S]-sulfate
(PerkinElmer), with or without 100 mM sodium chlorate. For
analyzing protein expression, another set of cells was incubated in
parallel with L-Methionine and L-cysteine free DMEM medium
(GIBCO), supplemented with 200 mCi of [
35S]-labeled cysteine-
methionine mixture (PerkinElmer), with or without 100 mM
sodium chlorate. Cells were collected 24 hours later and lysed with
solubilization buffer containing 100 mM (NH4)2SO4, 20 mM Tris
(pH 7.5), 20% glycerol, and 1% 3-[(-cholamidopropyl) dimethy-
lammonio]-2-hydroxyl-1-propanesulfonic acid (CHAPSO, Ana-
trace, Maumee, Ohio) in the presence of 16 complete protease
inhibitor mixture (Roche Molecular Biochemicals, Indianapolis,
Ind.). Cell lysates were incubated overnight at 4uC with protein A
sepharose beads (GE Healthcare) and washed three times with
PBS containing 0.1%Tween 20. Finally, proteins were eluted from
the beads by 2XSDS buffer separated by 12% SDS-PAGE, and
visualized by autoradiogram.
Generation of scFvFc-TM/VSV-G pseudotyped
lentiviruses and 293T cells stably expressing scFvFc-TM
through lentiviral transduction
A self-inactivating pHAGE lentivector (a gift from R. Mulligan)
was modified to accommodate subcloning of Sfi-I/Pac-I scFvFc-
TM DNA fragments. pHAGE lentivector has a CMV promoter
that drives the expression of the transgene. It also expresses the
Zoanthus Green Fluorescent protein (ZsGreen) gene via an IRES
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transduction efficiencies.
For the production of VSV-G pseudotyped lentiviral particles,
total of 5610
6 293T cells were seeded on 100 mm diameter plates,
and co-transfected the next day with 10 mg of the pHAGE
lentivector and packaging plasmids (10 mg HIV-1 Gag-Pol, 1 mg
pCMV-Rev1b, and 2.5 mg pCMV-VSV-G), using the Ca-
Phosphate method. At 48 and 72 hours post transfection,
supernatant was collected and cleared by centrifugation
(2100 rpm; 15 minutes) and sterile filtered through a 0.45 mm
filter. Viral supernatant was concentrated by ultracentrifugation
(21,000 rpm; 2 hours) through a 20% sucrose cushion, aliquoted
and stored at 280uC. The titer of the pseudotyped virus particles
was evaluated either by RT assay or by transduction of HeLa cells
with increasing dilutions of the lentivirus stock and measurement
of ZsGreen marked cells or APC-anti-human Fc staining by FACS
analysis. Importantly, incorporation of the scFvFc-CD28/CD28-
gp41 fusion protein did not lower the titer of viral particles (data
not shown).
293T cells were transduced, in the presence of 8 mg/ml
polybrene, with above generated recombinant lentiviruses at
different MOI as indicated for 4 hours. Functional scFvFc
expression on the transduced cell surface was analyzed by FACS,
following a similar protocol as described above, first at 48 hours
post-trandsuction then again after longer periods of propagation to
confirm stable scFvFc expression. Biotinylated peptide or protein
antigens and their concentration used for specific antibody binding
analysis are described in the figure legends.
Incorporation of functional scFvFc-TM proteins into
lentivirus particles
Viral capture assay. A 96-well plate was coated with
different antigens overnight at 4uC, using a coating buffer-
NaCO3/HCO3 (pH 9.6). The following antigens were used:
commercial biotinylated TRM peptide 50 mM, biotinylated GD03
(S1-RBD)-Fc 20 mg/ml, or 20 mg/ml BSA. Duplicated wells were
blocked with 1% BSA at 4uC for 1.5 hour prior to incubation with
equal amounts of concentrated lentiviral particles (based on
reverse transcription activity) expressing on their surface either the
11A or PS11 scFvFc antibodies for additional 1.5 hour at 4uC.
Wells were then washed 5 times with 200 ml PBS and reverse
transcription analysis was performed on eluted particles.
Western blot analysis. Equal amounts (based on p24
antigen levels) of concentrated lentiviruses were lysed using
RIPA lysis buffer (50 mM Tris-HCl pH 7.4; 150 mM NaCl;
1 mM PMSF; 1 mM EDTA; 1% NP-40; 1% sodium
deoxycholate; 0.1% SDS) supplemented with protease inhibitors
(Roche, Indianapolis, Ind.) and resolved by SDS-PAGE under
reducing conditions. Upon transfer, nitrocellulose membranes
were blocked with 5% skim milk and proteins were probed with a
mouse anti HIV-1-p24-HRP antibody (Immuno-Diagnostics), or a
goat anti-human Fc-HRP antibody (Pierce) followed by detection
using an enhanced chemiluminescence kit (Amersham).
Immunofluorescence of pseudotyped viruses. Hela cells
grown overnight on 12 mm cover-slips were incubated at 4uC for
30 minutes with media containing 10 mM HEPES, pH-8.0,
followed by incubation for additional 2 hours with VSV-G
pseudotyped viral particles expressing surface PS11-scFvFc-
CD28-gp41-ZsGreen, or control ZsGreen virus. Samples were
fixed with 3.9% paraformaldehyde (SIGMA) for 30 minutes. Cells
were washed once more with PBS and incubated with PBS/0.1 M
glycine (SIGMA) for 10 minutes, followed by another wash in PBS
and permeabilization with PBS 0.05% saponin (SIGMA) for
30 minutes. Samples were then blocked with PBS supplemented
with 2% BSA and 0.05% saponin for 30 minutes and incubated
with either a mouse anti-p24 antibody (AG3.0; NIH AIDS
Research and Reference Reagent Program) or with an anti-human
Fc-rhodamine antibody (Jackson ImmunoResearch) for 1 hour.
Cells were then washed and incubated with Cy2-labeled anti-
mouse IgG antibody (Jackson ImmunoResearch) for an additional
hour. Controls include virus-bound cells incubated with the
secondary antibody alone. Finally, samples were mounted for
fluorescence microscopy by using ProLong antifade kit
(Invitrogen). Images were acquired by using BIO-Rad Radiance
2000 laser scanning confocal microscope using a Nikon 606.
ScFvFc quantification on the surface of transfected or
transduced cells
To quantify the number of scFv-Fc molecules on the surface of
transiently transfected or lentivirus transduced cells, the ‘‘Quantum
Simply cellular anti-mouse IgG kit’’ was used (Bangs Laboratories,
Inc.). Briefly, cells expressing on their surface the scFvFc with a C9
tag were incubated with 10 mg of an APC conjugated mouse anti-
C9 monoclonal antibody 1D4 (Invitrogen-Molecular Probes) for
1 hour on ice in PBS supplemented with 2% BSA. Calibration
beadswith knownbindingcapacityofmouseIgGmoleculesontheir
surface were treated with the same conditions as the cells. Upon
washing, both cells and calibration beads were analyzed for APC
staining intensity by FACS. Number of scFv-Fc molecules on cell
surface was determined by plotting a calibration curve, using the
QuickCal quantitative software from Bangs labs.
Isolation and enrichment of rare 11A scFvFc expressing
cells
Transduction, ZsGreen sorting, and antigen staining of
scFvFc expressing cells. As a model for the isolation of rare
antibody from a population of scFvFc expressing cells, 293T cells
were transduced with lentiviruses encoding either 11A scFvFc or
PS11 scFvFc at MOI of one. The transduced cells were propagated
for one week to ensure stable expression and then sorted based on
their ZsGreen expression. Upon further propagation, ZsGreen
sorted cells were counted and mixed at the depicted ratio of 11A/
PS11 scFvFc. For the detection and isolation of 11A scFvFc
transduced cells, total mixed cells were blocked with 2% BSA for
30 minutes followed by staining with biotinylated GD03-Fc at an
optimized concentration of 2.65 mg/ml (GD03-Fc protein was
biotinylated using the EZ-link NHS-biotin, PIERCE) for
30 minutes on ice. Cells were then washed 3 times with PBS and
stained with streptavidin-APC in PBS/2% BSA.
Magnetic beads enrichment and FACS sorting of APC-
positive 11A scFvFc expressing cells. Following staining with
APC-Streptavidin, cells were washed and re-suspended in 500 ml
PBS buffer containing 0.5% BSA and 2 mM EDTA. Cells were
then labeled with MACS-anti-APC magnetic beads (20 ml/
10
7 cells, Miltenyi) for 10 minutes at room temperature. Single-
cell suspension was loaded on pre-washed MS magnetic columns
that were placed in a magnetic field. Upon removing unbound
cells through 3 times of washing, APC labeled cells were recovered
by removing the columns from the magnetic field and plunging the
cells using 1 ml of the above buffer. Cells isolated by anti-APC
magnetic beads were analyzed by FACS. Two populations of APC
positive cells, R2 and R3, were sorted. Upon propagation for one
week, APC positive R2 and R3 sorted cells were divided into two
portions. One part was subjected to PCR isolation of scFvFc
fragments. Amplified scFvFc fragments were cloned into the
TOPO TA cloning vector (Invitrogen) followed by DNA
sequencing. Rest of the cells were further propagated for 1–2
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surface scFvFc by biotinilated GD03-Fc and APC-Streptavidin.
Inhibition of SARS-CoV spike protein pseudotyped
lentiviral infection by cell-surface displayed 80R scFvFc
SARS-CoV spike protein (TOR2 strain) pseudotyped lentivi-
ruses, expressing a luciferase reporter gene, were incubated at 4uC
for 30 minutes with increasing concentrations of 293T cells
expressing on their surface the anti-TOR2 spike 80R-scFvFc or
with cells expressing PS11-scFvFc on their surface as a control.
Both 80R- and PS11-scFvFc surface-expressing cells were also
incubated with VSV-G pseudotyped viral particles for the analysis
of non-specific viral absorption. Following absorption, viral
supernatant was used to infect 293T cells expressing the ACE2
receptor as described [23]. Neutralization of infection was
determined by measuring the luciferase activity in the target cells
following transduction, using EG&G Berthold Microplate Lumi-
nometer.
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